George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
IC on line bulletin today has BTG as a buy again following this morning's results
Positive piece in today's on line IC report. Even allowing for the legal decision, BTG still materially undervalued: BTG�s (BTG) varicose veins treatment Varithena has finally been assigned a permanent insurance code in the US. Doctors who implement the procedure will be entitled to up to $1,697 (�1,292) reimbursement via the government�s Medicare and Medicaid insurance programmes, meaning prescription is now expected to pick up. Varithena insurance has been the thorn in BTG�s side since 2015 when the treatment was first launched in the US. Originally, its temporary code meant doctors could only expect up to $1,129 back from the insurers, short of the $3,000 it costs for use on multiple veins. Without guaranteed reimbursement, doctors have been reluctant to prescribe Varithena and sales have fallen far short of expectations during the past two years. But even with these new codes, broker Panmure Gordon remains cautious about forecasting an uptick in sales due to competition in the market. And even chief executive Louise Makin is still reluctant to get excited, warning that the impact on physician adoption and insurer practice might not become clear before the end of 2018. Investor enthusiasm for the announcement was also dampened by news that BTG will have to take a �53.5m provision in its upcoming first-half results due to problems surrounding another product. A Delaware court has found the group guilty of breaching the terms of its distribution agreement with peer WellStat, regarding chemotherapy toxicology treatment Vistogard. WellStat claimed the UK group had failed to invest in a large enough sales force in the US. BTG has been forced to pay damages and will lose the US rights to the treatment. BTG is considering its appeal options. Considering Vistogard only contributed �3.5m of sales in the year to March 2017, this news won�t have muddied the outlook too much. However, the one-off provision is sure to impact half-year results, due on 14 November. IC View Poor publicity regarding a small number of insignificant drugs has dogged BTG�s share price for the past few years. The shares are up on solidly our recent buy tip (652p, 25 May 2017). Although some sentiment has been recovered by the promise of new Varithena codes, we think the shares� forward earnings valuation of 25 times � far below the top of its five-year valuation range � fails to account for the growth available in some of BTG�s key markets. Buy."
BTG...pushing on up to Interims on the 14th Nov. EPS seen increasing 84% and P/E of 25 to 2018, (Hist Low)Numis have a 900p SP Target 😎😃 https://pbs.twimg.com/media/DNnV021XUAAeVHp.jpg
BTG analysis.......... https://simplywall.st/news/2017/10/19/what-do-analysts-think-about-the-future-of-btg-plcs-lsebtg-business/
FTSE 100 one day ,
A couple of quid up on last year though when it felt more like a breakDOWN
How many different forums are you posting that message....
BTG Btg yearly and 6 month breakout. Brokers have been bullish recently. eg, 05 Oct 17 Numis Buy 741.00 900.00 900.00 Reiterates. Broker Upgrade --- 17-Oct-2017 05:16:40 - BTG PLC BTG.L: JEFFERIES RAISES TARGET PRICE TO 900P FROM 775P; RATING BUY. http://uk.advfn.com/p.php?pid=legacydaily&epic=L^BTG&type=4&size=2&period=5&ind_type1=1&ind1_1=&ind2_1=&olx_1=3&ma_type1=3&o_1maday1=25&o_2maday1=&o_colour1=1&olx_2=3&ma_type2=3&o_1maday2=200&o_2maday2=&o_colour2=2&scheme=&delay_indices=DELAYED_INDICES
People strangely buy after it tops out, something I used to end up doing. Unless it means the SP has more legs come the update??? thoughts
Up she goes and we're still a few weeks away from results. Close down report was encouraging.
that's alright by me........a bit more buying and selling happening but still not a lot
The share price is rising, that's all that matters :)
Very quiet on here to-day so far. Any thoughts anyone????
share price is holding considering the news .
Looks like a stable stock
....no more action until November's update???
...........or still bouncing off the buffers. Has to be the most frustrating share going. Hard to understand why it isn't flying. Either the BODs are incompetent or there is something strange going on.
heading for former highs of 740p
RNS Number : 9323G Louise and Rolf cash in another bundle of share options - KERCHING!!!!! Meanwhile the share price keeps bouncing off the buffers. In the absence of a dividend, the only real prospect of getting a decent return from this share is a takeover bid.......
What's happening 8th June is there a update due ?
Out today enough is enough share price in free fall shorters paradise
I couldn't afford to take the hit this morning
Opportunity to average down ?
I cannot find any mention of the D* word anywhere in the results. BTG seems to be becoming mature - their word, some might say ex growth. *Dividend
I'll drink to that £7-50